ReviewJournal of the neurological sciences2017
Management of glioblastoma in elderly patients.
Review in Journal of the neurological sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.Journal of neuro-oncology · 2026Article
- Assessment of the RANO-resect criteria in elderly patients with glioblastoma.Journal of neuro-oncology · 2025Article
- Pericytes Are Immunoregulatory Cells in Glioma Genesis and Progression.International journal of molecular sciences · 2024Review
- Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment.Journal of neuro-oncology · 2024Article
- Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Glioblastoma management in a lower middle-income country: Nationwide study of compliance with standard care protocols and survival outcomes in Ukraine.Neuro-oncology practice · 2023Article
- Role of DNA methylation in the relationship between glioma risk factors and glioma incidence: a two-step Mendelian randomization study.Scientific reports · 2023Article
- Palliative care of older glioblastoma patients in neurosurgery.Journal of neuro-oncology · 2022Review
- Recurrent glioblastoma in elderly: Options and decision for the treatment.Surgical neurology international · 2022Review
- Molecular Biology in Treatment Decision Processes-Neuro-Oncology Edition.International journal of molecular sciences · 2021Review
- Article
- PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging.Aging · 2021Review
- Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.Frontiers in oncology · 2021Article
- CircNUP98 Suppresses the Maturation of miR-519a-3p in Glioblastoma.Frontiers in neurology · 2021Article
- Clinical neuro-oncology for the neurologist.Neurology. Clinical practice · 2020Review
- Lysosomes in glioblastoma: pump up the volume.Cell cycle (Georgetown, Tex.) · 2020Review
- Clinical Significance of Various Classification Standards of Age Groups in Predicting Survival of Patients with Glioblastoma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Viral vector: potential therapeutic for glioblastoma multiforme.Cancer gene therapy · 2020Review
- Surgical Management of Intracranial Meningiomas in the Elderly: Early and Long-term Outcomes.Clinical interventions in aging · 2020Article
- High Grade Glioma Treatment in Elderly People: Is It Different Than in Younger Patients? Analysis of Surgical Management Guided by an Intraoperative Multimodal Approach and Its Impact on Clinical Outcome.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm for elderly GBM patients continues to evolve due to the higher frequency of age-related and/or medical co-morbidities. Geriatric GBM patients have historically been excluded from larger, controlled clinical trials due to their presumed decreased likelihood of a sustained treatment response and/or a prolonged good outcome. Here, we highlight current treatment considerations of elderly GBM patients with respect to surgical, radiotherapeutic and systemic modalities, with considerations for improving future clinical outcomes for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.